AtriCure (ATRC) Stock Price, News & Analysis

Company Overview

AtriCure, Inc. (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures. AtriCure also offers the EPi-Sense system for hybrid AF ablation procedures that combine surgical and catheter-based approaches, along with related accessories and procedural support.

Founded in 2000 and headquartered in Mason, Ohio, AtriCure serves hospitals, cardiac surgeons and electrophysiologists in the United States and international markets. The company supports its products through clinical education, physician training and procedural programs aimed at expanding the use of surgical and hybrid therapies for AF.

Key Stats

• Today's Range: $59.13 to $61.70
• 50-Day Range: $33.00 to $60.77
• 52-Week Range: $25.36 to $61.70
• Volume: 1.30 million shs
• Average Volume: 1.40 million shs
• Market Capitalization: $3.10 billion
• P/E Ratio: 288.60
• Dividend Yield: N/A
• Price Target: $53.30
• Consensus Rating: Moderate Buy

AtriCure Stock Analysis - MarketRank™

AtriCure scored higher than 48% of companies evaluated by MarketBeat, and ranked 565th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AtriCure has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 7 buy ratings, 4 hold ratings, and no sell ratings.

Downside Risk

AtriCure has a consensus price target of $53.30, representing about 12.3% downside from its current price of $60.77.

Amount of Analyst Coverage

AtriCure has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 55.17%

Earnings Growth

Earnings for AtriCure are expected to grow by 55.17% in the coming year, from $0.29 to $0.45 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AtriCure is 289.39, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.93.

Price to Earnings Ratio vs. Sector

The P/E ratio of AtriCure is 289.39, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.39.

Price to Book Value per Share Ratio

AtriCure has a P/B Ratio of 6.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.76% of the float of AtriCure has been sold short.

Short Interest Ratio / Days to Cover

AtriCure has a short interest ratio ("days to cover") of 3.62, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AtriCure has recently increased by 3.34%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AtriCure does not currently pay a dividend.

Dividend Growth

AtriCure does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.63

News Sentiment

AtriCure has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for AtriCure this week, compared to 4 articles on an average week.

Search Interest

Only 4 people have searched for ATRC on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.

MarketBeat Follows

5 people have added AtriCure to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AtriCure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,317,897.00 in company stock.

Percentage Held by Insiders

4.00% of the stock of AtriCure is held by insiders.

Percentage Held by Institutions

99.11% of the stock of AtriCure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/23/2026
• Today: 9/25/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:ATRC
• CIK: 1323885
• Web: www.atricure.com
• Phone: (513) 755-4100
• Fax: 513-755-4567
• Employees: 1,350
• Year Founded: 2000

Price Target and Rating

• Average Price Target for AtriCure: $53.30
• High Price Target: $65.00
• Low Price Target: $36.00
• Potential Upside/Downside: -12.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.21
• Trailing P/E Ratio: 289.39
• Forward P/E Ratio: 209.55
• P/E Growth: N/A
• Net Income: -$11.45 million
• Net Margins: 1.85%
• Pretax Margin: 2.12%
• Return on Equity: 2.34%
• Return on Assets: 1.77%

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 4.22
• Quick Ratio: 3.19

Sales & Book Value

• Annual Sales: $534.53 million
• Price / Sales: 5.78
• Cash Flow: $0.32 per share
• Price / Cash Flow: 187.96
• Book Value: $9.89 per share
• Price / Book: 6.14

Miscellaneous

• Outstanding Shares: 50,870,000
• Free Float: 48,831,000
• Market Cap: $3.09 billion
• Optionable: Optionable
• Beta: 1.26